Business Context and Reporting Period
Company: Ultragenyx Pharmaceutical Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 11, 2016
Event Date: November 11, 2016
This filing reports a specific corporate event regarding the company's regulatory status in Europe. It does not contain a periodic financial report (e.g., 10-K or 10-Q).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a specific event rather than a financial statement.
Material Changes
- Regulatory Withdrawal: On November 11, 2016, Ultragenyx announced the withdrawal of its Marketing Authorization Application (MAA) from the European Medicines Agency (EMA).
- Product Affected: Aceneuramic Acid Prolonged Release (Ace-ER).
- Indication: Treatment of adult patients with GNE Myopathy.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) detailing the withdrawal but does not include specific forward-looking guidance, financial outlook, or detailed risk factors within the body of this 8-K text.
Contingencies: The withdrawal of the MAA represents a significant development in the company's European regulatory strategy for Ace-ER.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for the specific rationale behind the withdrawal of the Ace-ER application.
- Verify the impact of this withdrawal on the company's overall pipeline and European market strategy.
- Check subsequent filings for any updates on the status of Ace-ER in other jurisdictions or potential resubmission plans.